ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 0927 • ACR Convergence 2020

    Care Gap in Patients with Systemic Sclerosis with CXR Findings Suggestive of Fibrosis

    Sandeep Dhillon1, Jessica Kapralik2, Curtis Sobchak3, Nader Khalidi4, Martin Kolb5, Nathan Hambly2, Gerard Cox2, Karen Beattie4 and Maggie Larche4, 1McMaster University, Burlington, ON, Canada, 2McMaster University, Hamilton, 3McMaster University, St. Catharines, ON, Canada, 4McMaster University, Hamilton, ON, Canada, 5McMaster University and Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamliton, ON, Canada

    Background/Purpose: Lung involvement, including interstitial lung disease (ILD), is the leading cause of death in patients with systemic sclerosis (SSc). High resolution CT (HRCT) is…
  • Abstract Number: 1078 • ACR Convergence 2020

    Highly Reactive anti-Jo1 Autoantibodies to Distinct HisRS Variants and Domains Associate with Lung and Joint Involvement in Patients with Myositis

    Antonella Notarnicola1, Charlotta Preger2, Susanna L. Lundström2, Nuria Renard2, Edvard Wigren2, Eveline Van Gompel2, Angeles S. Galindo-Feria2, Helena Persson3, Maryam Fathi4, Johan Grunewald2, Per-Johan Jakobsson2, Susanne Gräslund2, Ingrid Lundberg5 and Cátia Fernandes-Cerqueira2, 1Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 2Karolinska Institutet, stockholm, Sweden, 3Science for Life Laboratories, KTH, Stockholm, Sweden, 4Karolinska University Hospital, stockholm, Sweden, 5Division of Rheumatology, Department of Medicine, Karolinska Institutet,, Stockholm, Sweden

    Background/Purpose: To address the reactivity and affinity against histidyl-transfer RNA synthetase (HisRS) autoantigen of anti-Jo1 autoantibodies from serum and bronchoalveolar lavage fluid (BALF) and associations…
  • Abstract Number: 1383 • ACR Convergence 2020

    Tocilizumab Shows Potential in Preserving Lung Function in Systemic Sclerosis with Positive anti-topoisomerase-1 (Scl-70): A Single Centre Cohort Study

    Yasir Suleman1, Kristina Clark2, Svetlana Nihtyanova3, Voon Ong4 and Christopher Denton2, 1Royal Free Hospital London NHS Trust, London, United Kingdom, 2University College London, London, United Kingdom, 3Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, 4UCL, London, United Kingdom

    Background/Purpose: Recent Phase II (faSScinate) and Phase III (focuSSced) clinical trials of tocilizumab versus placebo in early dcSSc highlighted the potential impact of tocilizumab on…
  • Abstract Number: 0929 • ACR Convergence 2020

    The Effect of Mycophenolate Mofetil on Pulmonary Function Tests in Patients with Systemic Sclerosis-associated Interstitial Lung Disease, and the Difference Between the African Americans versus Non-African Americans

    Afroditi Boulougoura1, Shannon Lance2, Duncan Moore3, Haijun Wang4, Julio Huapaya5 and Virginia Steen3, 1Department of Internal Medicine, Medstar Georgetown University Hospital, Washington, DC, USA., Washington, DC, 2Department of Internal Medicine, Medstar Georgetown University Hospital, Washington, DC, USA., Washington, 3Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, 4MedStar Health Research Institute, Washington, DC, USA, Washington, 5Department of Critical Care Medicine, National Institutes of Health, Bethesda, MD, USA., Bethesda

    Background/Purpose: Scleroderma-related interstitial lung disease (SSc-ILD) is a pulmonary fibrosing disorder characterized by systemic inflammation and progressive scarring of the lungs that leads to respiratory…
  • Abstract Number: 1082 • ACR Convergence 2020

    The Presence of Anti-Jo1, anti-PL7, And/or anti-MDA5 Antibodies in Idiopathic Inflammatory Myopathy Confers an Increased Risk of a Significant Restrictive Pulmonary Defect

    Dmitriy Cherny1 and Carrie Richardson1, 1Rush University Medical Center, Chicago, IL

    Background/Purpose: A subset of patients with idiopathic inflammatory myopathy develop significant restrictive lung disease, although risk factors for this are poorly defined. Autoantibodies may be…
  • Abstract Number: 1431 • ACR Convergence 2020

    Interstitial Lung Disease in Patients with ANCA Associated Vasculitis – a Prospective Single Centre Study

    Alojzija Hocevar1, Katja Perdan Pirkmajer1, Matija Tomsic1 and Ziga Rotar1, 1University Medical Center Ljubljana, LJUBLJANA, Slovenia

    Background/Purpose: Recently, an association between anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and interstitial lung disease (ILD) has been uncovered. We aimed to determine the rate…
  • Abstract Number: 0995 • ACR Convergence 2020

    Jo-1-Binding B Cells Undergo Limited Class-Switching but Are Biased Towards Autoreactive-Prone and Memory B Cell Subsets in Anti-histidyl-tRNA Synthetase Syndrome

    Jennifer Young-Glazer1, Alberto Cisneros2, Erin Wilfong1, Scott Smith1, Leslie J. Crofford1 and Rachel Bonami1, 1Vanderbilt University Medical Center, Nashville, TN, 2Vanderbit University Medical Center, Nashville, TN

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases traditionally classified as dermatomyositis or polymyositis, but these disorders are increasingly defined by the presence of…
  • Abstract Number: 1091 • ACR Convergence 2020

    A Computer-Aided Diagnostic System for Quantitative Scoring of Extent of Interstitial Lung Disease (ILD) in Dermatomyositis/Polymyositis Associated ILD

    Sangmee Bae1, Andrea Oh2, Grace Kim3, Jonathan Goldin3 and Christina Charles-Schoeman4, 1University of California Los Angeles, Los Angeles, CA, 2National Jewish Health, Denver, CO, 3University of California, Los Angeles, Los Angeles, 4University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Interstitial lung disease (ILD) occurs in up to 80% of patients with dermatomyositis (DM) and polymyositis (PM), and is a leading cause of morbidity…
  • Abstract Number: 1446 • ACR Convergence 2020

    Pregnancy Outcomes in Patients with Interstitial Lung Disease

    Aardra Rajendran1, Stephanie Giattino2, Amanda Eudy3, Aparna Swaminathan4 and Megan Clowse5, 1Duke University, Lewisville, NC, 2Duke University, Media, PA, 3Duke University, Durham, NC, 4Duke University, Durham, 5Duke University, Chapel Hill, NC

    Background/Purpose: Patients with interstitial lung disease (ILD) are often recommended to avoid conception or terminate pregnancy despite limited data on pregnancy outcomes and complications. Studies…
  • Abstract Number: 1046 • ACR Convergence 2020

    Risk Factors Associated with Interstitial Lung Disease in Patients with RA: Findings from a Retrospective Healthcare Database Analysis

    Joe Zhuo1, Qisu Zhang2, Keith Knapp3, Yuexi Wang4, Cynthia Gutierrez4, Ding He4, Lin Xie4, Sonie Lama1 and Gary Craig5, 1Bristol-Myers Squibb Company, Princeton, NJ, 2STATinMED Research (at time of analysis), Ann Arbor, MI, 3Discus Analytics LLC, Spokane, WA, 4STATinMED Research, Ann Arbor, MI, 5Arthritis Northwest, PLLC, Spokane, WA

    Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of RA and is associated with increased morbidity and mortality.1 Previous studies have shown variability in…
  • Abstract Number: 1096 • ACR Convergence 2020

    Assessing Interstitial Lung Disease in a Racially Diverse Population with Idiopathic Inflammatory Myositis

    Jammie Law1, Ana Valle2, Katherine Mullins3 and Shereen Mahmood4, 1Montefiore Medical Center, Bronx, NY, 2Albert Einstein College of Medicine, New York, NY, 3Montefiore Medical Center, BROOKLYN, NY, 4Albert Einstein College of Medicine / Montefiore Medical Center, Wantagh, NY

    Background/Purpose: Interstitial lung disease (ILD) is a common extra-muscular manifestation of Idiopathic Inflammatory Myositis (IIM) and increases risk of mortality. Prior studies and registries have focused on either smaller cohorts or predominantly Caucasian/European populations. Our aim was to better characterize the…
  • Abstract Number: 1523 • ACR Convergence 2020

    Pulmonary Cytokine, Chemokine and Growth Factor Profiles of Distinct Radiographic Patterns of Interstitial Lung Disease in Systemic Sclerosis

    Elizabeth Volkmann1, Donald Tashkin2, Ning Li2, Mei Leng2, Grace Kim2, Jonathan Goldin2, Airi Harui2 and Michael Roth2, 1University of California, Los Angeles, Los Angeles, CA, 2University of California, Los Angeles, Los Angeles

    Background/Purpose: The radiological hallmarks of systemic sclerosis-related interstitial lung disease (SSc-ILD) include interstitial inflammation (ground glass opacity) with reticular changes (fibrosis). The precise pathobiology of…
  • Abstract Number: 0041 • ACR Convergence 2020

    Association of the RPA3-UMAD1 Locus with Interstitial Lung Diseases Complicated with Rheumatoid Arthritis in Japanese

    Yuya Shirai1, Suguru Honda2, Katsunori Ikari3, Masahiro Kanai4, Yoshito Takeda5, Yoichiro Kamatani6, Takayuki Morisaki7, Eiichi Tanaka8, Atsushi Kumanogoh9, Masayoshi Harigai10 and Yukinori Okada11, 1Osaka university, Suita, Japan, 2Tokyo Women's Medical University, Tokyo, Japan, 3Tokyo Women's Medical University, Shinjuku, Japan, 4Harvard Medical School, Boston, 5Osaka university, Osaka, 6Graduate School of Frontier Sciences, the University of Tokyo, Tokyo, Japan, 7The institute of Medical Science, the University of Tokyo, Tokyo, Japan, 8Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, 9Osaka university, Osaka, Japan, 10Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, 11Osaka University Graduate School of Medicine, Osaka, Japan

    Background/Purpose: The genetic background of rheumatoid arthritis-interstitial lung disease (RA-ILD) has been evaluated in Europeans, but little knowledge has been obtained in non-Europeans. In particular,…
  • Abstract Number: 1047 • ACR Convergence 2020

    Prospective Analysis of a Cohort of Patients with Interstitial Lung Disease Associated with Connective Tissue Disease and Their Response to Immunosuppression with Mycophenolate Mofetil and Rituximab

    Yan Li1, Hassan Baig2, Carlos Rojas2, Justin Stowell2, Elizabeth Lesser2, Shalmali Borkar2, Andy Abril1 and Isabel Mira-Avendano1, 1Mayo Clinic, Ponte Vedra Beach, FL, 2Mayo Clinic, Jacksonville, FL

    Background/Purpose: Connective tissue diseases (CTDs) are commonly identified causes for interstitial lung disease (ILD). Compared with idiopathic interstitial pneumonias, patients with CTD-ILD and interstitial pneumonia…
  • Abstract Number: 1158 • ACR Convergence 2020

    Clinical Features and Outcomes in STING-Associated Vasculopathy with Onset in Infancy (SAVI)

    Sofia Torreggiani1, Sara Alehashemi2, Jacob Mitchell1, Gema Souto Adeva1, Bin Lin1, Jenna Wade1, Gina Montealegre Sanchez3, Abdulrahman Alrasheed4, Sibel Balci5, Roberta Berard6, Borzutzky Arturo7, Jürgen Brunner8, Bjoern Buehring9, Al Adba Buthaina10, Caterina Cancrini11, John Carter12, Mireia Corbeto Lopez13, Fabrizio De Benedetti14, Huy Do15, Gregor Dueckers16, Les Folio15, Antonella Insalaco17, Rabia Miray Kisla Ekinci5, Michael Miller18, Marco Montes Cano19, Marie-Paule Morin20, Seza Ozen21, Lucia Pacillo11, Suzanne Ramsey22, Adam Reinhardt23, Dax Rumsey24, Laisa Santiago25, Grant Schulert26, Benjamin Wright27, Adriana de Jesus28 and Raphaela Goldbach-Mansky29, 1Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, 2Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, 3NIAID/NIH, Rockville, MD, 4King Abdullah Specialized Children Hospital, Riyadh, Riyadh, Saudi Arabia, 5Department of Pediatric Rheumatology, Cukurova University Faculty of Medicine, Adana, Turkey, 6London Health Sciences Centre, London, ON, Canada, 7Pontificia Universidad Católica de Chile, Santiago, Chile, 8Tirol Kliniken, Innsbruck, Innsbruck, Austria, 9Rheumazentrum Ruhrgebiet, Ruhr-University-Bochum, Herne, Germany, 10Sidra Medicine, Doha, Doha, Qatar, 11Unit of Immune and Infectious Diseases, Scientific Institute for Research and Healthcare (IRCCS) Childrens’ Hospital Bambino Gesù, University Department of Pediatrics (DPUO); Department of Systems Medicine, University of Rome Tor Vergata, Roma, Italy, 12University of South Florida, Tampa, FL, 13Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, 14Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 15Radiology and Imaging Sciences, Clinical Center, NIH, Bethesda, 16Helios Kliniken - Kinderklinik, HELIOS Klinikum Krefeld, Germany, Krefeld, Germany, 17Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 18Feinberg School of Medicine, Northwestern University Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 19Hospital Universitario Virgen del Rocío, Sevilla, Sevilla, Spain, 20Université de Montréal, CHU Sainte-Justine, Montréal, Canada, 21Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, 22IWK Health Centre, Dalhousie University, Halifax, NS, Canada, 23Boys Town National Research Hospital, Omaha, Omaha, NE, 24Alberta Health Services – Edmonton Zone (Stollery Children’s Hospital), University of Alberta, Edmonton, AB, Canada, 25Johns Hopkins All Children's Hospital, St. Petersburg, FL, 26PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 27Mayo Clinic, Phoenix, AZ, 28Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, 29Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD

    Background/Purpose: STING-Associated Vasculopathy with Onset in Infancy (SAVI) is an autoinflammatory interferonopathy caused by gain-of-function mutations in STING1, characterized by peripheral vasculopathy and interstitial lung…
  • « Previous Page
  • 1
  • …
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • 47
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology